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Abstract
Background/Objectives: Febrile neutropenia (FN) occurs in up to 80% of patients
with hematologic malignancies. Evidence suggests using extended infusions (EI) of
beta-lactams can improve outcomes in some populations, but there is limited clinical literature comparing cefepime standard infusion (SI) versus EI for FN. The FDA-
approved regimen for FN was used at a large community teaching hospital for patients
with FN until a hospital-wide EI beta-lactam protocol was introduced that allowed
for EI cefepime in FN at the physicians' discretion. We sought to compare outcomes
between patients with FN who received SI and EI cefepime.
Methods: Patients with acute myeloid or lymphocytic leukemia who developed FN
between April 2014 and January 2021 were included in this single-center, retrospective study. The primary outcome was to compare mean time to defervescence after
the initiation of cefepime SI or EI regimens. SI regimens consisted of IV cefepime 2G
q8h/0.5 h, and EI regimens as IV cefepime 1G q8h/4 h. Secondary outcomes included
30-day all-cause mortality, hospital length of stay (LOS), duration of cefepime, and
need to escalate therapy.
Results: Overall, 193 patients were included. Baseline characteristics were similar between groups. Time to defervescence was significantly shorter with EI compared with
the SI group (median 48 h [48–100.5] vs. 70 h [48–113], p = 0.005). Cefepime duration
of therapy was significantly shorter in the EI compared with the SI group (median
6.0 days vs. 8.0 days, p = 0.002). There was no difference between other secondary
outcomes including LOS, mortality, and antibiotic escalation.
Conclusion: Despite reduced total daily dose of cefepime, EI cefepime administered
as a 1G/0.5 h LD followed 2 h later by 1G q8h/4 h for FN acutely achieves more rapid
defervescence than the FDA-approved SI regimen and ultimately attains comparable
patient outcomes.
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I NTRO D U C TI O N

to utilize the EI 1G q8h/4 h or SI 2G q8h/0.5 h regimen for FN.4
Though the ASP did not have clinical literature to support standard-

Febrile neutropenia (FN) is defined as an absolute neutrophil count

izing cefepime EI 1G q8h/4 h for all FN patients at the time, there

(ANC) of <500 cells/mm3 or an expected ANC decrease to <500

were concerns for SI regimens inconsistently achieving MICs to the

cells/mm3 during the next 48 h, plus a temperature ≥ 38.3°C (101 °F)

CLSI susceptibility breakpoint of 8 mg/L for Pseudomonas aeruginosa;

once or ≥ 38.0°C (100.4 °F) sustained over an hour, per Infectious

literature reports a PK/PD breakpoint range between 4 and 8 mg/L

Diseases Society of America (IDSA) guidelines.1 Patients who de-

for SI 2G q8h/0.5 h regimens.6,10 Alternatively, the EI regimen of 1G

3

q8h/4 h consistently achieves PK/PD breakpoints of 8 mg/L in hos-

or neutropenia lasting >7 days have a higher risk of developing fever.

pitalized patients.8,11 Based on these differences in achievable PK/

Up to 80% of patients with hematologic malignancies develop FN,

PD breakpoints and limited literature, this study aimed to compare

yet pathogens are only isolated in 20–30% of patients.1,2

the clinical outcomes for those with FN who received cefepime 2G

velop profound neutropenia as defined by an ANC <100 cells/mm

Cefepime is the only FDA-approved anti-pseudomonal beta-

q8h/0.5 h and cefepime 1G/0.5 h LD followed by 1G q8h/4 h.

lactam for FN. The National Comprehensive Cancer Network
(NCCN) and IDSA guidelines recommend empiric regimens consisting of an anti-pseudomonal beta-lactam such as cefepime,
piperacillin-t azobactam, or a carbapenem.1-3 Extended infusion (EI)
regimens optimize the pharmacodynamics (PD) of beta-lactam an-
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2.1 | Study design

tibiotics by capitalizing on their time-dependent activity. The PD
target for cephalosporins is achieved when the free-drug concentra-

This single-center, retrospective, non-inferiority study was con-

tion is greater than the minimum inhibitory concentration (fT > MIC)

ducted at a 706-bed quaternary care community teaching hospi-

of the organism for at least 60–70% of the dosing interval.4-6 EI

tal in Memphis, Tennessee. Patients were identified by specific FN

cefepime improves achievability of PD targets in a variety of pa-

ICD-9-CM and ICD-10-CM diagnosis codes. A review of the medi-

tient populations, but cefepime was optimized in pharmacokinetic

cal record and laboratory markers was conducted to confirm the

(PK) models of critically ill patients with a diagnosis of ventilator-

FN diagnosis for study enrollment consideration. Patients were

associated pneumonia.7

included if they were ≥ 18 years, had a diagnosis of acute myeloid

In April 2016, the Antimicrobial Stewardship Program (ASP)

leukemia (AML) or acute lymphoblastic leukemia (ALL), had admis-

evaluated literature and implemented a facility-wide EI beta-lactam

sion FN diagnosis or diagnosis during admission, and received intra-

protocol utilizing a dosing strategy of cefepime 1G/0.5 h loading

venous cefepime with one of the following regimens: cefepime 2G

dose (LD) to rapidly achieve therapeutic plasma concentrations fol-

q8h/0.5 h or cefepime 1G Q8h/4 h. Patients were excluded if they

lowed 2 h later by 1G q8h/4 h to target organisms with an MIC up

had a documented cephalosporin allergy or if they received another

to 8 mg/L.8 During the first 24 h of therapy, patients in the EI group

anti-pseudomonal beta-lactam for >24 h prior to receiving cefepime.

received a total of 4G of cefepime and the SI group received 6G of

Receipt of other antibiotic agents (e.g., vancomycin) did not disqual-

cefepime. Following the first 24 h of therapy, there was a 50% re-

ify the patient from inclusion. During this time, vancomycin was the

duction in doses between the EI and SI group, 3G and 6G respec-

standard of care agent of choice for anti-MRSA therapy initiated in

tively. The ASP aimed to implement a standardized dosing regimen

FN patients admitted to this community teaching hospital. Patients

throughout the entire hospital, and 1G q8h/4 h was chosen for

were enrolled in reverse chronological order for a study period of

several reasons. Standardizing all cefepime regimens to 2G q8h/4 h

April 2014 to January 2021. The study was approved by the local

would be largely unnecessary in most patients from a PK/PD per-

IRB, which waived the requirement for informed consent due to the

spective as it achieves concentrations to target a PK/PD breakpoint

retrospective nature of the study.

of 16 mg/L, which would treat Pseudomonas aeruginosa with an intermediate susceptibility.9 Furthermore, there were safety concerns
regarding drug-induced encephalopathy if this dosing strategy was

2.2 | Outcomes/Definitions

utilized for all patients. Finally, though cefepime was not overly
expensive when this was implemented, it was one of the primary

The primary outcome was median time to defervescence after the

agents used empirically for hospital-associated infections. The au-

initiation of cefepime EI or SI regimens. Defervescence was defined

thors estimated that utilizing a standardized dosing regimen of 2G

as an oral temperature ≤ 100.4 °F for at least 48 h.12 Time to defer-

q8h/4 h compared with 1G Q8h/4 h would cost the institution an

vescence was collected as time from last known febrile timepoint,

additional $50,000.00 annually based on cefepime cost and utiliza-

which included the 48-h window. Secondary outcomes included

tion patterns at the time.

30-day all-cause mortality, hospital length of stay (days), duration of

Published literature evaluating cefepime EI dosing for FN is lim-

cefepime (days), and incidence of therapy escalation (e.g., changing to

ited to one study that showed no difference in clinical outcomes be-

a different anti-pseudomonal agent such as piperacillin-t azobactam).

tween two groups when comparing cefepime 2G q8h/0.5 h versus

Infection-related mortality was not collected due to the retrospec-

2G q8h/3 h, thus it was left to provider discretion at our institution

tive nature of this project design. All patients in the EI group received
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a LD based on the facility's dosing protocol, but not all patients in the

as measures of central tendency. Results did not differ after trim-

SI group received a LD. Patients who received a second dose within

ming outliers ±3 standard deviations from the mean; therefore, all

a timeframe prior to the scheduled frequency were considered to

data points were analyzed. Categorical data were analyzed using a

have received a LD. AKI on admission was defined as an increase in

Pearson χ2 or Fisher's exact test. Linear regression was used to com-

13

serum creatinine (SCr) 0.3 mg/dl or 1.5 times baseline SCr.

All pa-

tients in the EI group were candidates to receive EI cefepime based

pute the relationship between the primary outcome. An a priori α
value of 0.05 was identified for statistical significance.

on the facility's renal dosing recommendations for cefepime in FN.
Infection source was confirmed with positive cultures and documentation of the site of infection, whereas a suspected infection site was

3
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deemed such through documentation in the medical record (e.g., CT
indicating pneumonia without positive cultures). The facility's micro-

A total of 993 patients were reviewed and overall, 800 patients were

biology laboratory utilized Vitek®2 from April 2014 to April 2016

excluded; the most common reasons for exclusion were no diagnosis

and MALDI-TOF plus BD Phoenix™ from May 2016 through the end

of AML or ALL and alternative cefepime dosage regimen (Figure 1).

of the study period for culture identification and susceptibility re-

The remaining 193 patients received cefepime and were separated

porting. Though there were not enough isolates to evaluate micro-

into the SI group (n = 95) or EI group (n = 98).

biology and resistance trends specifically in this patient population,

Cefepime treatment group inclusion was independent of all

these did not change at the institution-level during the study time

baseline characteristics and demographics (Table 1) excluding: a

frame. Of note, none of the hospital-specific treatment protocols

greater number of patients in the EI group exhibited baseline pro-

for acute leukemia changed during this time including chemotherapy

calcitonin abnormalities [χ2(1) = 4.5, p < 0.05], potassium (K) abnor-

agents, supportive care management, antimicrobial prophylaxis, and
treatment protocols for FN.

malities [χ2(1) = 6.8, p < 0.01], and granulocyte colony-stimulating

factor (GCS-F ) administration [χ2(1) = 8.5, p < 0.01]; whereas,
more patients in the SI group had reported lactate dehydrogenase

2.3 | Statistical analysis

(LDH) abnormalities [χ2(1) = 11.5, p < 0.001] and met SIRS criteria

[χ2(1) = 13.3, p < 0.001]. Most individuals receiving the SI (n = 81,
77.1%) were derived from the first time period of data collection

Previously published data suggested a 22 h difference in time to

(range: 2014-April 2016), and majority of individuals receiving the

defervescence when evaluating cefepime 2G q8h/0.5 h vs. 2G

EI (n = 74, 84.1%) were derived from the second period (range: April

q8h/3 h.4 The software R(™⟩ version 4.1.1 was used to assist in

2016–2021), χ2(1) = 69.4, p < 0.001. No statistical difference was

calculations and modeling. Variables were screened to evaluate

found when analyzing patients with AKI on presentation in the SI or

assumptions of normality, homogeneity of variance, linearity, mul-

EI group (Table 1). There was no difference in the median baseline

ticollinearity, and homogeneity of regression. All continuous vari-

APACHE II scores at time of admission between the SI and EI groups

ables violated the Shapiro–Wilk test (p < 0.05) indicating a deviation

(16.0 [IQR 14–18] vs. 16.0 [IQR 13–18.8], p = 0.78). Additionally,

from normality. Mann–Whitney U tests were computed to evaluate

there was no difference in GCS-F duration, days since receipt of

group differences. Medians and interquartile ranges were recorded

chemotherapy, documented administration of antibiotic prophylaxis

F I G U R E 1 Flow diagram of study
design
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TA B L E 1 Baseline demographics
Standard infusion (n = 95)

Extended infusion (n = 98)

p-value

Median age, years

61.0

64.0

0.35

Male, n (%)

60 (63.2)

50 (51.0)

0.09

AML, n (%)

73 (76.8)

79 (80.6)

0.52

ALL, n (%)

22 (23.2)

19 (19.4)

0.52

Median weight, kg (IQR)

77.1 (65.7–91.9)

77.5 66.7–91.2)

0.81

Median baseline eGFR, ml/min (IQR)

77.6 (64.6–104.9)

83.9 (60.0–112.0)

0.98

Total patients with AKI, n (%)

10 (10.5)

14 (14.3)

0.43

Presented with AKI, n (%)

6 (6.3)

11 (11.2)

0.32

Developed AKI, n (%)

4 (4.2)

3 (3.1)

0.67

Mean LOS when AKI developed, days (±SD)

4.0 ± 2.2

3.7 ± 1.5

0.83

Median duration of AKI, days

7.0

3.0

0.23

Abnormal LDH at baseline, n (%)

53 (55.8)

31 (31.6)

< 0.001

Abnormal LA at baseline, n (%)

30 (31.6)

24 (24.5)

0.27

Abnormal PCT at baseline, n (%)

12 (12.6)

24 (24.5)

0.03

Abnormal K at baseline, n (%)

18 (18.9)

35 (35.7)

0.009

SIRS criteria met at baseline, n (%)

87 (91.6)

71 (72.4)

< 0.001

Median APACHE II (IQR)

16.0 (14.0–18.0)

16.0 (13.0–18.8)

0.78

Median duration of neutropenia, days (IQR)

10.0(5.0–22.0)

13.5 (6.3 to 23.8)

0.15

History of HSCT, n (%)

25 (26.3)

27 (27.6)

0.85

Documented prophylaxis prior to treatment, n (%)

54 (65.9)

52 (55.9)

0.65

Receipt of Vancomycin, n (%)

70 (70.7)

69 (72.6)

0.85

Administration, n (%)

21 (23.2)

42 (42.9)

0.004

Median duration, days (IQR)

3.0(2.3–8.0)

5.0 (3.0–9.0)

0.29

11.5 (5.0–14.3)

7.0 (2.0–14.3)

0.30

GCS-F

Median time since most recent GCS-F administration,
days (IQR)

Note: Continuous variables were analyzed using Mann–Whitney U tests, and categorical variables were analyzed using Pearson χ2 or Fisher's exact
test.
Abbreviations: AKI, (acute kidney injury) was defined by increase in serum creatinine (SCr) 0.3 from baseline or 1.5 times baseline SCr; ALL, acute
lymphocytic leukemia; AML, acute myeloid leukemia; APAHCE II, Acute Physiology and Chronic Health Evaluation scoring tool; GCS-F, granulocyte
colony-stimulating factor; HSCT, hematopoietic stem cell transplant; K, baseline potassium; LA, baseline lactic acid; LDH, baseline lactate
dehydrogenase; LOS, length of stay; PCT, baseline procalcitonin.

prior to starting treatment for FN, or receipt of vancomycin between

(n = 80, 84.2% in SI and n = 86, 87.8% in EI; Figure 2). However,

the SI and EI groups.

at 24 h, 48 h, and 72 h a greater proportion of the patients in the EI

Most patients in the SI group received cefepime 2G Q8h/0.5 h

group defervesced (Figure 2).

(n = 78, 82.1%) while a minority (n = 17, 17.9%) had an adjustment

Kaplan–Meier analyses were performed to determine the SI and

to 2G q12h/0.5 h or 2G q24h/0.5 h due to reduced estimated cre-

EI treatment groups' cumulative rates of defervescence. Log-rank

atinine clearance (eCrCl). Similarly, the majority (n = 93, 94.9%) of

tests showed SI and EI group rates did not differ over the full 168 h

patients in the EI group received 1G Q8h/4 h, while a small minority

time window, χ2(1) = 3.4, p = 0.07 (Figure 2A). The Peto and Peto

(n = 6, 5.1%) received 1G q12h/4 h for reduced eCrCl based on ap-

modification of the Gehan-Wilcoxon test was conducted to focus

proved pharmacy and therapeutics committee dosing protocols.

assessment to the left-side of the plot, and Kaplan–Meier curves

Mann–Whitney U tests were used to examine the difference in

showed significant differences between the rates of defervescence

the primary outcome after initiation of cefepime (Table 2). Median

at earlier time periods, χ2(1) = 8.1, p = 0.004. When restricted to a

time to defervescence in the EI group (48 h, IQR = 48–100.5) was

72-h time window, log-rank tests showed the rate of defervescence

significantly more rapid than in the SI group (70 h, IQR = 48–113,

was greater in the EI group compared with the SI group, χ2(1) = 8.6,

p = 0.005).

p = 0.003 (Figure 2D).

All patients, whether they received the SI or EI treatment, defer-

Linear regression analyses determined cefepime treatment

vesced within 168 h, and most patients broke fever within 144 h

groups (β = −13.53, p = 0.04) significantly predicted time to
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TA B L E 2 Time to defervescence and
secondary outcomes
Median time to defervescence, h (IQR)

Standard
infusion (n = 95)

Extended
infusion (n = 98)

p-value

70.0 (48–113.0)

48.0 (48–100.5)

0.04

Defervescence by 168 h, n (%)

95 (1)

98 (1)

Defervescence by 144 h, n (%)

80 (84.2)

86 (87.8)

0.62

Defervescence by 120 h, n (%)

74 (77.9)

78 (79.6)

0.91

–

Defervescence by 96 h, n (%)

65 (68.4)

73 (74.5)

0.44

Defervescence by 72 h, n (%)

49 (51.6)

67 (68.4)

0.03

Defervescence by 48 h, n (%)

32 (33.7)

50 (51.0)

0.02

Defervescence by 24 h, n (%)

1 (1.10)

21 (21.4)

< 0.001

30-day all-c ause mortality, n (%)

12 (12.6)

Median hospital length of stay, days (IQR)

10 (10.2)

5

0.60

19.0 (8.0–29.0)

18.0 (8.0–3 0.0)

0.95

Median cefepime duration, days (IQR)

8.0 (5.0–12.0)

6.0 (3.3–8.0)

0.002

Antimicrobial escalation, n (%)

21 (22.1)

23 (23.5)

0.82

Note: Continuous variables were analyzed using Mann–Whitney U tests, and categorical variables
were analyzed using Pearson's χ2 or Fisher's exact test.

defervescence (R 2 = 0.02, F1,191 = 4.29, p = 0.04). Using a Bonferroni-

4
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DISCUSSION

suggested p-value <0.2, other clinical variables (LDH, procalcitonin,
GCS-F, SIRS, and cefepime LD) were considered for inclusion in the

The goal of this study was to assess whether exploiting the time-

model. However, due to a lack of clinical relevance, only SIRS criteria

dependent PK property of cefepime using an EI regimen would per-

were included as a control.

form as well as the FDA-approved SI regimen in patients with FN

When controlling for SIRS criteria in the overall analysis, the
model no longer predicted time to defervescence (R

2

despite the 50% dose reduction.

= 0.02,

Of note, 10 SI patients and 10 EI patients had definitive culture

F2,189 = 2.34, p = 0.10), even though cefepime treatment

growth with susceptibilities (Tables S1 and S2). Despite the small

group was contributing to the variance explained in the model

number of Pseudomonas isolates reported as susceptible when the

(β = −14.52, p = 0.03). When restricting the sample to only SIRS

PD target did not support achievement of the CLSI breakpoint MIC,

criteria, time to defervescence was significantly shorter with EI

we still found patients with FN who received the EI cefepime reg-

cefepime (M = 68.11) compared to SI (M = 86.94), t(157) = 2.64,

imen defervesced more quickly. This finding provides clinical sup-

p < 0.01. Because our Kaplan–M eier curves suggested the 24–72 h

port in optimizing the beta-lactam dosing strategy to account for

time window was relevant (Figure 2A–D), we investigated each

PK changes in patients with FN. Any patient with an infection can

time point while controlling for SIRS criteria. When controlling

potentiate SIRS that can lead to sepsis. This septic picture can con-

for SIRS criteria, EI vs. SI treatment groups significantly predicted

tribute to augmented renal clearance (ARC) that can lead to low-

time to defervescence at 24 h (β = 0.21, p < 0.001; R 2 = 0.10,

ered fT > MIC and increased risk of therapeutic failure when PD of

F2,190 = 3.39, p = 0.04), and 72 h (β = 0.41, p = 0.01; R 2 = 0.04,

limited specifically in the FN population, ARC in the FN population

F2,190 = 3.67, p = 0.03).

has been associated with subtherapeutic concentrations of vanco-

F2,190 = 11.05, p < 0.001), 48 h (β = 0.26, p = 0.01; R 2 = 0.04,

Cefepime duration of therapy as a secondary outcome was sig-

agents, such as beta-lactams, are not optimized.13 While literature is

mycin and piperacillin.15,16

nificantly shorter in the EI group compared with SI [median 6.0d

The effect of using EI cefepime dosing regimens has been eval-

vs. 8.0d, p = 0.002]. 30-day all-cause mortality (10.2% vs 12.6%,

uated in other disease states. Bauer and colleagues conducted a

p = 0.60), hospital LOS (18d vs. 19d, p = 0.95) and incidence of ther-

retrospective experimental study at a tertiary medical center that

apy escalation (23% vs. 23.5% p = 0.82) was not statistically differ-

compared EI cefepime 2G q8h/4 h vs. SI cefepime 2G q8h/0.5 h in

ent between the EI and SI regimens (Table 2).

87 patients with Pseudomonas aeruginosa bacteremia or pneumonia.

Microbiology data were also evaluated (Tables 3, S1, and S2).

They found a significant reduction in mortality (1 vs. 11; p = 0.03)

More patients in the EI group (n = 39, 39.8%) had a confirmed or

and ICU length of stay (8d vs. 18.5d; p = 0.04) when utilizing the EI

suspected site of infection compared to the SI group (n = 22,
2

regimen.5

23.2%), χ (1) = 6.2, p < 0.05. Collection of any culture did not differ

Literature evaluating EI cefepime for FN is limited to one, single-

(p = 0.62) between EI (n = 90, 91.8%) and SI (n = 89, 93.7%) groups.

center, prospective, randomized, comparative, pilot study. Patients

Additionally, there was no difference (p = 0.18) in prevalence of

were randomized to receive cefepime 2G q8h/0.5 h or cefepime 2G

positive cultures between EI (n = 38, 38.8%) and SI (n = 46, 48.4%)

q8h/3 h. Time to defervescence was 22 h shorter in the 3-h EI group;

groups (Table 3).

however, this finding did not reach statistical significance. Though no
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F I G U R E 2 Kaplan–Meier curves and log-rank tests evaluating group differences in time to defervescence
TA B L E 3 Microbiology data

Standard infusion
(n = 95)

Extended infusion
(n = 98)

p-value

Any culture collected, n (%)

89 (93.7)

90 (91.8)

0.62

Confirmed or suspected site of
infection, n (%)

22 (23.2)

39 (39.8)

0.01

Positive culture, n (%)

46 (48.4)

38 (38.8)

0.18

24 (25.5)

16 (16.3)

0.12

Urine, n (%)

17 (17.9)

18 (18.4)

0.93

Sputum, n (%)

13 (13.8)

9 (9.2)

0.31

2 (2.0)

1.00

Growth from culture
Blood, n (%)

Miscellaneous, n (%)

a

2 (2.1)
2

Note: Categorical variables were analyzed using Pearson χ or Fisher's exact test.

a

Wound, stool.

statistically significant difference in time to defervescence was ob-

with FN. Significantly more patients in the EI vs SI group achieved

served, this could represent a clinically significant outcome in critically

the primary endpoint of overall clinical response (74.4% vs. 55.1%,

ill patients with FN. There was no difference between groups for 30-

p = 0.044). Significance persisted for those with a documented in-

day mortality, hospital LOS, or incidence of antimicrobial escalation.4

fection for EI and SI groups (68.4% vs. 35.7%, p = 0.039) and patients

A separate study evaluated piperacillin-tazobactam and cef-

with a diagnosis of pneumonia for EI and SI groups (n = 4/5, 80%

tazidime EI (4 h, n = 47) vs. SI (0.5 h, n = 58) regimens in patients

vs. n = 0/8, 0%, p = 0.007), respectively.17 Fehér and colleagues
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conducted a retrospective observational study reviewing neutrope-

are limited. Similar median APACHE II scores between the SI and the

nic patients who presented with fever after having received hema-

EI groups (16.0 [14.0–18.0] vs. 16.0 [13.0–18.8], p = 0.78) demon-

topoietic stem-cell transplantation or induction chemotherapy for

strate another strength of this study in that clinical disease severity

AML. Eighty-eight patients received meropenem 1G q8h as either an

was similar between groups. Furthermore, exclusion of patients who

EI or SI. Treatment success was superior in the EI vs. SI group (68.4%

received a different anti-pseudomonal beta-lactam for >24 h before

18

Finally, a randomized, multicenter, open-label,

starting cefepime ensures that the difference observed in the pri-

superiority clinical trial is currently enrolling hospitalized patients

mary outcome was not due to an initial exposure of an alternative

with hematologic malignancy meeting criteria for FN and treated with

anti-pseudomonal agent.

vs. 40.9%, p < 0.001).

cefepime, piperacillin-tazobactam, or meropenem. Patients will be

This study is not without limitations; this is a single-center, ret-

randomized 1:1 to EI and SI for each antibiotic. The primary endpoint

rospective study meaning data collection relied on accurate doc-

will be clinical efficacy, defined as defervescence without modifying

umentation in patients' charts. Moreover, collection of fever prior

the antibiotic treatment within the first 5 days of therapy.19

to admission involved subjective reporting of fever from outside

From an antimicrobial stewardship perspective, these findings

hospitals or by patients at home. Not having access to this infor-

are significant in showing that utilizing a 50% reduced dose EI reg-

mation could potentially influence either group if patients were afe-

imen provided a significantly faster time to defervescence com-

brile on admission and remained afebrile while receiving treatment.

pared with the FDA-approved SI regimen. Between the EI and the SI

However, the percentage of patients who had a one-time fever

groups, there was a statistical difference in treatment duration (me-

occurrence prior to admission did not differ between the EI and SI

dian 6.0 days vs. 8.0 days respectively, p = 0.002); however, these

groups (15 vs. 15, p = 0.93).

align with recommendations for duration of treatment of FN based

The authors could not account for why more patients in the EI

on NCCN and IDSA guidelines which reflect a duration of treatment

group received GCS-F (42.9% vs. 23.2%, p = 0.004); none of the

targeting a suspected source or empiric duration of 3–5 days if pa-

hospital-specific treatment protocols for acute leukemia changed

tient is afebrile with no infection identified or at least 7 days depend-

during the study timeframe. However, we do not expect this finding to

ing on ANC count recovery.1–3

impact our primary outcome as evidenced by no difference between

This strategy can capitalize on the PD of cefepime and improve

duration of neutropenia (10.0d vs. 13.5d, p = 0.15). The low yield of

the likelihood of achieving the PD breakpoint while also represent-

organisms and organisms with elevated MIC data found in this study

ing a potential significant cost savings to hospitals that can reduce

is reflective of real-world data. It does limit the ability to extrapolate

their cefepime spending by 50%. This dosing stratagem is not FDA-

these results to a patient population with frequent infections due to

approved, so local epidemiology and patient populations should be

pathogens with high cefepime MICs.1,2 Similarly, a continuous urine

evaluated prior to implementing a lower EI dose of cefepime for FN.

collection to accurately calculate eCrCl was not standard of care

Studies evaluating patients with FN have demonstrated altered PK

during this timeframe; thus, investigators were not able to determine

including volume of distribution and clearance, which can lead to

how many patients may have had ARC. Though data are not currently

subtherapeutic concentrations of antimicrobials.16,20,21 Alternative

available to estimate the PK/PD breakpoint for cefepime 1G Q8h/4 h

cefepime dosing regimens should be considered when patients are

in patients with ARC, external application of these study results should

admitted with FN and especially when they have additional risk fac-

be used with caution in a patient population known to have ARC.11

14

tors for ARC (e.g., admit directly to ICU).

Finally, receipt of antipyretic agents (e.g., acetaminophen) or ste-

Dose optimizing cefepime in FN by utilizing this strategy may re-

roids was not recorded. These agents were available to all patients

duce incidence of adverse drug events as well as the development

through admission protocol orders and provider discretion. Though

of drug resistance. Cefepime-induced neurotoxicity is thought to be

a limitation of the study, the admission protocol orders for AML,

associated with multiple factors including hospital LOS, prolonged

ALL, and FN did not change during the study timeframe, and receipt

antibiotic exposure, and renal insufficiency. 22 Likewise, a study re-

of these agents represents a real-world scenario in which these

viewing exposure to cefepime, piperacillin-t azobactam, and mero-

agents were available to all patients as needed.

penem for severe sepsis or septic shock revealed each additional
day of exposure beyond the guideline-recommended duration of
treatment was associated with a 4% increased risk of new resistance

5

|
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within 60 days of initiation. 23 In our study, we found in the EI dosing
strategy a shortened time to defervescence, which resulted in over-

In conclusion, EI cefepime administered as a 1G/0.5 h LD followed 2 h

all shorter durations of treatment that might lead to fewer adverse

later by 1G q8h/4 h for FN resulted in shorter time to defervescence

events due to over exposure of cefepime.

compared with the FDA-approved SI dosing regimen. Using EI dosing

In addition to evaluation of dosing strategies optimized to

and exploiting the time-dependent property of cefepime appears to

achieve appropriate cefepime exposure, a strength of this study is

overcome the dose reduction from 2G Q8h/0.5 h and could be con-

the restriction of the patient population to those with ALL and AML.

sidered as an empiric regimen for patients with acute leukemia with an

By only including patients with these hematologic malignancies, con-

admission or in-hospital diagnosis of FN. Future prospective studies

founders based on other oncology disease-specific characteristics

are needed to explore whether employing this EI dosing strategy of
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cefepime for FN and shortening time to defervescence reduces incidence of adverse effects associated with cefepime as well as hospital
length of stay or delay in chemotherapy administration.
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